Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Upcoming Events and Highlights
Investor News
Share Price / Index
November 20, 2025
Not intended for U.S. and UK Media
U.S. FDA grants accelerated approval to Bayer’s HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant non-small cell lung cancer
November 19, 2025
Not intended for U.S. and UK Media
Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer
November 12, 2025
Business figures for the third quarter:
Bayer confirms 2025 Group outlook, progresses on strategic priorities
Discover More
